CN101256190A - Ca15-3、cea、ca19-9、ca12-5、sf乳腺癌胶体金五联检诊断试剂盒 - Google Patents
Ca15-3、cea、ca19-9、ca12-5、sf乳腺癌胶体金五联检诊断试剂盒 Download PDFInfo
- Publication number
- CN101256190A CN101256190A CNA2008100848354A CN200810084835A CN101256190A CN 101256190 A CN101256190 A CN 101256190A CN A2008100848354 A CNA2008100848354 A CN A2008100848354A CN 200810084835 A CN200810084835 A CN 200810084835A CN 101256190 A CN101256190 A CN 101256190A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- cea
- breast cancer
- aurosol
- pad
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 52
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 52
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 239000003153 chemical reaction reagent Substances 0.000 title description 10
- 238000007689 inspection Methods 0.000 title description 10
- 238000001514 detection method Methods 0.000 claims abstract description 35
- 238000003745 diagnosis Methods 0.000 claims abstract description 21
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 20
- 239000010931 gold Substances 0.000 claims abstract description 20
- 229910052737 gold Inorganic materials 0.000 claims abstract description 20
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 20
- 210000002966 serum Anatomy 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000002245 particle Substances 0.000 claims abstract description 16
- 239000000084 colloidal system Substances 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000003365 glass fiber Substances 0.000 claims description 7
- 241001494479 Pecora Species 0.000 claims description 6
- 230000000274 adsorptive effect Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 230000002494 anti-cea effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 25
- 238000012360 testing method Methods 0.000 abstract description 14
- 239000000427 antigen Substances 0.000 abstract description 9
- 102000036639 antigens Human genes 0.000 abstract description 9
- 108091007433 antigens Proteins 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 6
- 241000282414 Homo sapiens Species 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 238000004587 chromatography analysis Methods 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 102000008857 Ferritin Human genes 0.000 description 5
- 108050000784 Ferritin Proteins 0.000 description 5
- 238000008416 Ferritin Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000123 paper Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000003317 immunochromatography Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000031856 Haemosiderosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
显色组合 | 敏感性 | 特异性% |
CEA | 45.5 | 96.3 |
CA19-9 | 45.3 | 94.4 |
CA15-3 | 60.4 | 97.1 |
SF | 36.7 | 91.9 |
CA12-5 | 49.6 | 94.9 |
CEA+CA19-9 | 71.1 | 95.2 |
CEA+CA15-3 | 76.8 | 98.4 |
CEA+SF | 61.1 | 92.5 |
CEA+CA12-5 | 71.4 | 95.6 |
CA19-9+CA15-3 | 78.5 | 97.7 |
CA19-9+SF | 63.7 | 94.4 |
CA19-9+CA12-5 | 68.7 | 96.7 |
CA15-3+SF | 77.0 | 98.2 |
CA15-3+CA12-5 | 78.8 | 93.6 |
SF+CA12-5 | 65.4 | 94.9 |
CEA+CA19-9+CA15-3 | 85.6 | 95.7 |
CEA+CA19-9+SF | 79.1 | 95.1 |
CEA+CA19-9+CA12-5 | 81.7 | 95.5 |
CEA+CA15-3+SF | 83.1 | 98.4 |
CEA+CA15-3+CA12-5 | 87.1 | 97.4 |
CEA+SF+CA12-5 | 78.2 | 96.2 |
CA19-9+CA15-3+SF | 85.3 | 97.7 |
CA19-9+CA15-3+CA12-5 | 87.1 | 98.3 |
CA19-9+SF+CA12-5 | 75.7 | 97.1 |
CA15-3+SF+CA12-5 | 85.7 | 98.2 |
CEA+CA19-9+CA15-3+SF | 87.4 | 98.1 |
CEA+CA19-9+CA15-3+CA12-5 | 88.6 | 98.7 |
CEA+CA19-9+SF+CA12-5 | 84.5 | 97.8 |
CEA+CA15-3+SF+CA12-5 | 88.1 | 98.9 |
CA19-9+CA15-3+SF+CA12-5 | 88.2 | 98.4 |
CEA+CA19-9+CA15-3+SF+CA12-5 | 89.0 | 99.8 |
CEA | CA19-9 | CA15-3 | SF | CA12-5 | |
阳性 | 455 | 453 | 604 | 367 | 496 |
阴性 | 545 | 547 | 396 | 633 | 504 |
CEA | CA19-9 | CA15-3 | SF | CA12-5 |
阳性 | 504 | 498 | 354 | 524 | 484 |
阴性 | 496 | 502 | 646 | 476 | 516 |
变色组合 | 显色 | 不显色 |
CEA | 37 | 963 |
CA19-9 | 56 | 944 |
CA15-3 | 29 | 971 |
SF | 81 | 919 |
CA12-5 | 51 | 949 |
CEA+CA19-9 | 48 | 952 |
CEA+CA15-3 | 16 | 984 |
CEA+SF | 75 | 925 |
CEA+CA12-5 | 44 | 956 |
CA19-9+CA15-3 | 23 | 977 |
CA19-9+SF | 56 | 944 |
CA19-9+CA12-5 | 37 | 967 |
CA15-3+SF | 18 | 982 |
CA15-3+CA12-5 | 64 | 936 |
SF+CA12-5 | 51 | 949 |
CEA+CA19-9+CA15-3 | 43 | 957 |
CEA+CA19-9+SF | 49 | 951 |
CEA+CA19-9+CA12-5 | 45 | 955 |
CEA+CA15-3+SF | 16 | 984 |
CEA+CA15-3+CA12-5 | 26 | 974 |
CEA+SF+CA12-5 | 38 | 962 |
CA19-9+CA15-3+SF | 23 | 977 |
CA19-9+CA15-3+CA12-5 | 17 | 983 |
CA19-9+SF+CA12-5 | 29 | 971 |
CA15-3+SF+CA12-5 | 18 | 982 |
CEA+CA19-9+CA15-3+SF | 19 | 981 |
CEA+CA19-9+CA15-3+CA12-5 | 13 | 987 |
CEA+CA19-9+SF+CA12-5 | 22 | 978 |
CEA+CA15-3+SF+CA12-5 | 11 | 989 |
CA19-9+CA15-3+SF+CA12-5 | 16 | 984 |
CEA+CA19-9+CA15-3+SF+CA12-5 | 2 | 998 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810084835A CN101256190B (zh) | 2008-03-27 | 2008-03-27 | Ca15-3、cea、ca19-9、ca12-5、sf乳腺癌胶体金五联检诊断试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810084835A CN101256190B (zh) | 2008-03-27 | 2008-03-27 | Ca15-3、cea、ca19-9、ca12-5、sf乳腺癌胶体金五联检诊断试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101256190A true CN101256190A (zh) | 2008-09-03 |
CN101256190B CN101256190B (zh) | 2012-09-19 |
Family
ID=39891167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810084835A Expired - Fee Related CN101256190B (zh) | 2008-03-27 | 2008-03-27 | Ca15-3、cea、ca19-9、ca12-5、sf乳腺癌胶体金五联检诊断试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101256190B (zh) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102375055A (zh) * | 2010-08-19 | 2012-03-14 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种多重检测免疫层析芯片 |
CN101609096B (zh) * | 2009-07-21 | 2012-11-07 | 上海师范大学 | 肺癌标志物检测免疫层析试纸的制备方法 |
CN101738470B (zh) * | 2008-11-06 | 2013-04-03 | 益思美诠生物科技(上海)有限公司 | 能同时对多种分析物进行检测的免疫层析方法 |
CN103048469A (zh) * | 2012-12-06 | 2013-04-17 | 苏州海吉亚生物科技有限公司 | 双抗体组织细胞蛋白定量检测方法 |
CN103604925A (zh) * | 2013-11-26 | 2014-02-26 | 卢氏实验室公司 | 一步快速和监控肿瘤的免疫检测条 |
CN103901207A (zh) * | 2013-05-07 | 2014-07-02 | 上海良润生物医药科技有限公司 | Cystatin S和CA15-3在制备诊断和预示乳腺癌标志物中的应用 |
CN103913575A (zh) * | 2013-05-07 | 2014-07-09 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂s与糖类抗原19-9的联合应用 |
CN103913576A (zh) * | 2013-05-07 | 2014-07-09 | 上海良润生物医药科技有限公司 | Cystatin SN 和CA15-3在制备诊断和预示乳腺癌标志物中的应用 |
CN104422764A (zh) * | 2013-09-04 | 2015-03-18 | 深圳市艾瑞生物科技有限公司 | 糖蛋白类肿瘤标志物免疫层析试纸条及其制备方法与应用 |
CN104823051A (zh) * | 2012-10-05 | 2015-08-05 | 韦拉克斯生物医学股份有限公司 | 多分析物试验 |
CN104849465A (zh) * | 2015-05-29 | 2015-08-19 | 广州华弘生物科技有限公司 | 肿瘤血清标志物ca153、cea、hcg乳腺癌三联诊断试剂盒及其制备方法 |
CN105044339A (zh) * | 2015-06-25 | 2015-11-11 | 天津大学 | 一种新型的乳腺癌量子点免疫层析试纸条的制备方法 |
CN106841621A (zh) * | 2017-04-06 | 2017-06-13 | 黑龙江省科学院高技术研究院 | 肿瘤标志物cea快速检测试纸 |
CN106950373A (zh) * | 2017-03-29 | 2017-07-14 | 杭州博拓生物科技股份有限公司 | 一种ca15‑3半定量检测试剂盒及制备工艺 |
CN109633158A (zh) * | 2018-12-20 | 2019-04-16 | 黑龙江省科学院高技术研究院 | 乳腺癌肿瘤标志物ca153双阈值快速检测试纸条及其制备方法 |
CN114409789A (zh) * | 2022-03-30 | 2022-04-29 | 北京科跃中楷生物技术有限公司 | 一种胶体金颗粒标记方法及检测试剂盒 |
CN114560944A (zh) * | 2022-03-30 | 2022-05-31 | 北京科跃中楷生物技术有限公司 | 胶体金颗粒标记的抗体及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1296711C (zh) * | 2004-05-14 | 2007-01-24 | 沈阳迈迪生物医学技术有限公司 | 乳腺癌的Her-2免疫组织化学诊断试剂盒 |
CN1928563B (zh) * | 2005-09-09 | 2010-04-28 | 上海张江生物技术有限公司 | 乳腺癌的免疫组化诊断试剂盒和测试片 |
-
2008
- 2008-03-27 CN CN200810084835A patent/CN101256190B/zh not_active Expired - Fee Related
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101738470B (zh) * | 2008-11-06 | 2013-04-03 | 益思美诠生物科技(上海)有限公司 | 能同时对多种分析物进行检测的免疫层析方法 |
CN101609096B (zh) * | 2009-07-21 | 2012-11-07 | 上海师范大学 | 肺癌标志物检测免疫层析试纸的制备方法 |
CN102375055A (zh) * | 2010-08-19 | 2012-03-14 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种多重检测免疫层析芯片 |
CN104823051A (zh) * | 2012-10-05 | 2015-08-05 | 韦拉克斯生物医学股份有限公司 | 多分析物试验 |
CN103048469A (zh) * | 2012-12-06 | 2013-04-17 | 苏州海吉亚生物科技有限公司 | 双抗体组织细胞蛋白定量检测方法 |
CN103901207A (zh) * | 2013-05-07 | 2014-07-02 | 上海良润生物医药科技有限公司 | Cystatin S和CA15-3在制备诊断和预示乳腺癌标志物中的应用 |
CN103913575A (zh) * | 2013-05-07 | 2014-07-09 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂s与糖类抗原19-9的联合应用 |
CN103913576A (zh) * | 2013-05-07 | 2014-07-09 | 上海良润生物医药科技有限公司 | Cystatin SN 和CA15-3在制备诊断和预示乳腺癌标志物中的应用 |
CN103913575B (zh) * | 2013-05-07 | 2016-02-10 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂s与糖类抗原19-9的联合应用 |
CN103913576B (zh) * | 2013-05-07 | 2016-03-16 | 上海良润生物医药科技有限公司 | Cystatin SN 和CA15-3在制备诊断和预示乳腺癌标志物中的应用 |
CN103901207B (zh) * | 2013-05-07 | 2016-02-10 | 上海良润生物医药科技有限公司 | Cystatin S和CA15-3在制备诊断和预示乳腺癌标志物中的应用 |
CN104422764A (zh) * | 2013-09-04 | 2015-03-18 | 深圳市艾瑞生物科技有限公司 | 糖蛋白类肿瘤标志物免疫层析试纸条及其制备方法与应用 |
CN103604925A (zh) * | 2013-11-26 | 2014-02-26 | 卢氏实验室公司 | 一步快速和监控肿瘤的免疫检测条 |
CN104849465A (zh) * | 2015-05-29 | 2015-08-19 | 广州华弘生物科技有限公司 | 肿瘤血清标志物ca153、cea、hcg乳腺癌三联诊断试剂盒及其制备方法 |
CN104849465B (zh) * | 2015-05-29 | 2016-06-29 | 广州华弘生物科技有限公司 | 肿瘤血清标志物ca153、cea、hcg乳腺癌三联诊断试剂盒 |
CN105044339A (zh) * | 2015-06-25 | 2015-11-11 | 天津大学 | 一种新型的乳腺癌量子点免疫层析试纸条的制备方法 |
CN106950373A (zh) * | 2017-03-29 | 2017-07-14 | 杭州博拓生物科技股份有限公司 | 一种ca15‑3半定量检测试剂盒及制备工艺 |
CN106841621A (zh) * | 2017-04-06 | 2017-06-13 | 黑龙江省科学院高技术研究院 | 肿瘤标志物cea快速检测试纸 |
CN109633158A (zh) * | 2018-12-20 | 2019-04-16 | 黑龙江省科学院高技术研究院 | 乳腺癌肿瘤标志物ca153双阈值快速检测试纸条及其制备方法 |
CN114409789A (zh) * | 2022-03-30 | 2022-04-29 | 北京科跃中楷生物技术有限公司 | 一种胶体金颗粒标记方法及检测试剂盒 |
CN114560944A (zh) * | 2022-03-30 | 2022-05-31 | 北京科跃中楷生物技术有限公司 | 胶体金颗粒标记的抗体及其应用 |
CN114409789B (zh) * | 2022-03-30 | 2022-06-07 | 北京科跃中楷生物技术有限公司 | 一种胶体金颗粒标记方法及检测试剂盒 |
CN114560944B (zh) * | 2022-03-30 | 2022-08-09 | 北京科跃中楷生物技术有限公司 | 胶体金颗粒标记的抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101256190B (zh) | 2012-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101256190B (zh) | Ca15-3、cea、ca19-9、ca12-5、sf乳腺癌胶体金五联检诊断试剂盒 | |
CN101281198B (zh) | Ca27.29、tps、cyfra21-1乳腺癌胶体金三联检诊断试剂盒及其制备方法 | |
CN104849465B (zh) | 肿瘤血清标志物ca153、cea、hcg乳腺癌三联诊断试剂盒 | |
CN104515859A (zh) | 血红蛋白、血红蛋白-结合珠蛋白复合物、转铁蛋白联检试剂盒及其制备方法、检测方法 | |
CN104730258B (zh) | 一种便携式血型系统检测试纸及其检测方法 | |
CN101275954B (zh) | 一种简便快速测定人类i型胸苷激酶基因蛋白的乳癌预警芯片 | |
WO2000052463A9 (en) | Method of diagnosing and monitoring malignant breast carcinomas | |
CN110221084B (zh) | 一种快速检测he4和ca125的纳米硒试剂盒 | |
CN101520458B (zh) | 金标免疫分析检测hla-g及其抗体的简易方法 | |
AU632469B2 (en) | A method for early detection of lung cancer | |
CN105588944B (zh) | 检测agp1、serpina3和cdh1含量的系统在筛查活动性结核病患者中的应用 | |
CN104316685A (zh) | 一种二乙酰精胺的检测试剂盒及制备方法和应用 | |
CN204789589U (zh) | 一种胶体金检测试纸条 | |
CN107870234A (zh) | 一种检测甲状腺球蛋白浓度的试纸条及其制备方法 | |
CN102830234A (zh) | 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒 | |
CN102854324A (zh) | 快速无损伤性检测肝肿瘤标志物的方法以及采用的试纸条 | |
CN113109563B (zh) | 用于高危人群早期食管鳞癌筛查的标志物及其应用 | |
CN105572383A (zh) | 一种用于检测细胞角蛋白19的胶体金层析试纸条及其制备方法 | |
CN103808944B (zh) | 生物标志物vwf和adamts13及其在肝硬化诊断试剂中的用途 | |
CN108845143A (zh) | 一种pct-crp双联卡及其制备方法 | |
CN106198983A (zh) | 用于卵巢癌检测的试剂盒 | |
CN204719056U (zh) | 一种快速联合检测he4和ca125的试剂盒 | |
Udagawa et al. | Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT) | |
CN104931701A (zh) | 一种用于乳腺癌筛查的综合检测盒 | |
KR101083420B1 (ko) | 유방암 진단용 빈쿨린 자가항체 및 이를 이용한 진단키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING COMPULIFE BIOTECH RESEARCH CENTER Free format text: FORMER OWNER: HEILONGJIANG MEIKANG HUIRONG BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20120730 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 150001 HARBIN, HEILONGJIANG PROVINCE TO: 100070 FENGTAI, BEIJING |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120730 Address after: 100070, No. 5, building 15, No. 188, Fengtai science and Technology City, No. 8 South Fourth Ring Road, Beijing, Fengtai District Applicant after: Beijing Compulife Biotech Research Center Address before: 3, building 33, building 166, No. 150001 Hanjiang Road, Nangang District, Heilongjiang, Harbin Applicant before: Heilongjiang Meikang Huirong Biological Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing patent Biotechnology Research Center China Document name: Notification that Application Deemed not to be Proposed |
|
C56 | Change in the name or address of the patentee |
Owner name: BEIJING MOKOBIO BIOTECHNOLOGY RESEARCH CENTER CO., Free format text: FORMER NAME: BEIJING COMPULIFE BIOTECH RESEARCH CENTER |
|
CP03 | Change of name, title or address |
Address after: 100070, Beijing, Fengtai District, No. 188 South Fourth Ring Road headquarters base, No. 15, zone 5, building 8 Patentee after: BEIJING MOKOBIO BIOTECHNOLOGY RESEARCH CENTER Co.,Ltd. Address before: 100070, No. 5, building 15, No. 188, Fengtai science and Technology City, No. 8 South Fourth Ring Road, Beijing, Fengtai District Patentee before: Beijing Compulife Biotech Research Center |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100070, Beijing, Fengtai District, No. 188 South Fourth Ring Road headquarters base, No. 15, zone 5, building 8 Patentee after: BEIJING MOKOBIO LIFE SCIENCE Co.,Ltd. Address before: 100070, Beijing, Fengtai District, No. 188 South Fourth Ring Road headquarters base, No. 15, zone 5, building 8 Patentee before: BEIJING MOKOBIO BIOTECHNOLOGY RESEARCH CENTER Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120919 |